Monday, April 21, 2025 7:38:18 AM
I've presented clear evidence that disproves your claims.
Instead of addressing it with a reasoned response, you've defaulted to a simplistic reply lacking any supporting evidence.
You're out of your depth and it shows.
IsoPet (aka Radiogel) is typically administered in the range of about 200 Gy up to a maximum of 400Gy. I'll give you the benefit of doubt and go with a 500 Gy safety test.
IsoPet (aka Radiogel) is available at activities ranging from less than <1 mCi to about 30 mCi (approximately 37 to 1110 MBq).
Safety Test - 30-gram tumor(a typical mass for thyroid cancer
Manufactured Activity: A single vial at 30 mCi (30,000µCi)
Dosimetry Conversion: ~54? Ci of Y-90 delivers 100 Gy to 1g, i.e. about 1.85 Gy per µCi per gram
Even with a 5-day delay between manufacturing and testing, you can achieve a 500?Gy dose.
FYI - It doesn't take 5 days to ship to India unless you're going to walk it over there.
Instead of addressing it with a reasoned response, you've defaulted to a simplistic reply lacking any supporting evidence.
You're out of your depth and it shows.
IsoPet (aka Radiogel) is typically administered in the range of about 200 Gy up to a maximum of 400Gy. I'll give you the benefit of doubt and go with a 500 Gy safety test.
IsoPet (aka Radiogel) is available at activities ranging from less than <1 mCi to about 30 mCi (approximately 37 to 1110 MBq).
Safety Test - 30-gram tumor(a typical mass for thyroid cancer
Manufactured Activity: A single vial at 30 mCi (30,000µCi)
Dosimetry Conversion: ~54? Ci of Y-90 delivers 100 Gy to 1g, i.e. about 1.85 Gy per µCi per gram
Even with a 5-day delay between manufacturing and testing, you can achieve a 500?Gy dose.
FYI - It doesn't take 5 days to ship to India unless you're going to walk it over there.
Recent RDGL News
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:44:48 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/06/2026 05:15:04 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 03/04/2026 04:48:52 PM
- Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites • GlobeNewswire Inc. • 02/17/2026 01:30:00 PM
- Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ • GlobeNewswire Inc. • 02/10/2026 01:30:00 PM
- Vivos Inc Updates Human Therapy Progress in India • GlobeNewswire Inc. • 02/03/2026 01:30:00 PM
- Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals • GlobeNewswire Inc. • 01/28/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2026 04:06:21 PM
- Vivos Inc Summarizes Progress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 05:56:08 PM
- Vivos Inc Summarzes Preogress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 09:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 12:34:42 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:08:03 AM
- Vivos Inc. Issues Shareholder Update Letter • GlobeNewswire Inc. • 11/06/2025 01:30:00 PM
- Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics • GlobeNewswire Inc. • 10/29/2025 12:30:00 PM
- Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel® • GlobeNewswire Inc. • 10/27/2025 12:30:00 PM
- Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 05:46:00 PM
- Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:01:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 07:32:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2025 09:14:29 PM
